 The purpose of this study is to investigate the safety and initial efficacy of allogeneic adoptive immune therapy AAIT for advanced AIDS patients. 20 patients received i.v. transfusion one round 3 times of 2.0-3.010E8 cellskg of MNSs as the treated group. All of them received the conventional anti-opportunistic infection and ART treatment for AIDS. The side effects, symptom improvement, control of opportunistic infections and CD4 T cell numbers will be evaluated during the 48-week follow up. 